Evidence map›Paper›PMID 36045807›Full record

ArticleAnnals of medicine and surgery (2012)2022

Nabeela Fatima, Kiranmai Mandava, Fatima Khatoon, Juveria Badar, Syeda Fatima Begum, C Narasimhan, K Daljeet, Walli Mohammed

Open access · diamondAbstract read
In one paragraph

Article in Annals of medicine and surgery (2012), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
2.5field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 15 citations in OpenAlex.

  1. Observational
  2. Amiodarone Therapy: Updated Practical Insights.Journal of clinical medicine · 2024
    Review
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 1 institution in 1 country.

Nabeela FatimaDepartment of Pharmacy Practice, St Pauls College of Pharmacy, Turkayamjal, India.
Kiranmai MandavaDepartment of Pharmacy Practice, St Pauls College of Pharmacy, Turkayamjal, India.
Fatima KhatoonDepartment of Pharmacy Practice, St Pauls College of Pharmacy, Turkayamjal, India.
Juveria BadarDepartment of Pharmacy Practice, St Pauls College of Pharmacy, Turkayamjal, India.
Syeda Fatima BegumDepartment of Pharmacy Practice, St Pauls College of Pharmacy, Turkayamjal, India.
C NarasimhanSenior Cardiologist and Electrophysiologist, AIG Hospital, Hyderabad, India.
K DaljeetSenior Cardiologist and Electrophysiologist, AIG Hospital, Hyderabad, India.
Walli MohammedSenior Clinical Researcher, AIG Hospital, Hyderabad, India.
Asian Institute of Gastroenterology · IN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Amiodarone belongs to Class-III anti-arrhythmic drugs. It is one of the most effective anti-arrhythmic drugs used to treat or prevent several types of arrhythmias including atrial fibrillation, atrial flutter, ventricular tachycardia, and wide complex tachycardia, but unfortunately carries a high toxicity profile. Also, side effects of amiodarone involving various organs can be life-threatening. Materials & methods: This was an observational study carried out for six months i.e from April to September. The study included patients who are on amiodarone for greater than or equal to six months. The required data was collected in-person from the case sheets, treatment charts, and by interviewing the patients. The data for 67 patients was documented in suitable data collection form for analysis. Results: From our study data, it was noted that amiodarone was used for 3 different indications-atrial fibrillation, atrial flutter, and ventricular tachycardia. Among 67 patients enrolled, 38 had no side-effects. Side-effects data in the rest grouped basing on the organ system affected: 9 patients had renal effects, 6 patients had ophthalmic effects, 4 patients had endocrine effects, and 5 patients had hepatic effects. Conclusion: From our study, it is concluded that amiodarone is a safe and effective anti-arrhythmic drug at lower doses i.e. 200-1100 mg/week. When treated in lower doses of 1400-2800 mg/week, many side effects have been incident. Although these effects are mild and develop only after prolonged usage of the drug, it should be used judiciously.

Indexed as

AF, Atrial fibrillationAIH, Amiodarone induced hypothyroidismAIT, Amiodarone induced thyrotoxicosisAmiodaroneAtrial fibrillationAtrial flutterAV, AtrioventricularBMI, Body mass indexCPR, Cardiopulmonary resuscitationDEA, Des ethyl amiodaroneFDA, Food and drug administrationINR, International normalized ratioParoxysmal atrial fibrillationPSVT, Paraoxysmal supraventricular tachycardiaSGOT, Serum glutamic-oxaloacetic transaminaseSGPT, Serum glutamic pyruvic transaminaseSide-effectsVentricular tachycardiaVF, Ventricular FibrillationVT, Ventricular tachycardia

Identifiers

PMID36045807
PMCPMC9422214
OpenAlexW4285600520

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.